CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- S-3 Offering Registration Statement
- 10-K Report Annual Report
- POSASR Other POSASR
- 8-K Event Results of operations
- 4 Open-market sale Chief Legal Officer sold 4,169 shares at $3.15 ($13,145)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Option exercise Co-Chief Executive Officer acquired 36,310 shares (option exercise)
- 4 Open-market sale Chief Legal Officer sold 3,678 shares at $3.49 ($12,839)
- 4 Open-market sale Co-Chief Executive Officer sold 11,851 shares at $3.47 ($41,108)
- 4 Open-market sale Co-Chief Executive Officer sold 11,855 shares at $3.47 ($41,104)
- 4 Gift Director gave 27,910 shares (gift)
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 4 Open-market sale Co-Chief Executive Officer sold 7,471 shares at $4.04 ($30,202)
- 4 Open-market sale Co-Chief Executive Officer sold 7,471 shares at $4.05 ($30,232)
- 8-K Event Regulation FD disclosure
- 4 Open-market sale Chief Medical Officer sold 5,421 shares at $5.54 ($30,007)
Page 9 of 23 · 446 filings